Article

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017.

Department of Radiation Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama. .
Cancer (Impact Factor: 4.9). 05/2013; 119(10). DOI: 10.1002/cncr.27995
Source: PubMed

ABSTRACT BACKGROUND: Increased pathologic complete response (pCR) rates observed with neoadjuvant chemotherapy (NCT) for some subsets of patients with invasive breast cancer have prompted interest in whether patients who achieved a pCR can be identified preoperatively and potentially spared the morbidity of surgery. The objective of this multicenter, retrospective study was to estimate the accuracy of preoperative magnetic resonance imaging (MRI) in predicting a pCR in the breast. METHODS: MRI studies at baseline and after the completion of NCT plus data regarding pathologic response were collected retrospectively from 746 women who received treatment at 8 institutions between 2002 and 2011. Tumors were characterized by immunohistochemical phenotype into 4 categories based on receptor expression: hormone (estrogen and progesterone) receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative (n = 327), HR-positive/HER2-positive, (n = 148), HR-negative/HER2-positive, (n = 101), and triple-negative (HR-negative/HER2 negative; n = 155). In all, 194 of 249 patients (78%) with HER2-positive tumors received trastuzumab. Univariate and multivariate analyses of factors associated with radiographic complete response (rCR) and pCR were performed. RESULT: For the total group, the rCR and pCR rates were 182 of 746 patients (24%) and 179 of 746 patients (24%), respectively, and the highest pCR rate was observed for the triple-negative subtype (57 of 155 patients; 37%) and the HER2-positive subtype (38 of 101 patients; 38%). The overall accuracy of MRI for predicting pCR was 74%. The variables sensitivity, negative predictive value, positive predictive value, and accuracy differed significantly among tumor subtypes, and the greatest negative predictive value was observed in the triple-negative (60%) and HER2-positive (62%) subtypes. CONCLUSIONS: The overall accuracy of MRI for predicting pCR in invasive breast cancer patients who were receiving NCT was 74%. The performance of MRI differed between subtypes, possibly influenced by differences in pCR rates between groups. Future studies will determine whether MRI in combination with directed core biopsy improves the predictive value of MRI for pathologic response. Cancer 2013;. © 2013 American Cancer Society.

2 Followers
 · 
109 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Magnetic resonance imaging (MRI) has been widely applied in the contemporary management of patients with breast cancer and as a screening tool for those at increased risk; however, prospective evidence that the use of breast MRI improves patient outcomes remains limited to screening of known BRCA mutation carriers or women at increased risk based on a strong family history. Despite this, the role of MRI in the routine evaluation of the newly diagnosed breast cancer patient remains a subject of much debate, with widely divergent views on the value of MRI in selecting local therapy. The application of MRI in patients undergoing neoadjuvant therapy is an area of active investigation, with several potential benefits, including predicting response to therapy. We review the current state of the literature on the topics of MRI for screening, MRI and short-term surgical outcomes, MRI and long-term surgical outcomes, and MRI and neoadjuvant chemotherapy as presented at the 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium, 9 March 2013.
    Annals of Surgical Oncology 10/2013; 21(1). DOI:10.1245/s10434-013-3307-9 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this prospective pilot study, the feasibility of non-contrast dedicated breast computed tomography (bCT) to determine primary tumor volume and monitor its changes during neoadjuvant chemotherapy (NAC) treatment was investigated. Eleven women who underwent NAC were imaged with a clinical prototype dedicated bCT system at three time points - pre-, mid-, and post-treatment. The study radiologist marked the boundary of the primary tumor from which the tumor volume was quantified. An automated algorithm was developed to quantify the primary tumor volume for comparison with radiologist's segmentation. The correlation between pre-treatment tumor volumes from bCT and MRI, and the correlation and concordance in tumor size between post-treatment bCT and pathology were determined. Tumor volumes from automated and radiologist's segmentations were correlated (Pearson's r = 0.935, P < 0.001) and were not different over all time points [P = 0.808, repeated measures analysis of variance (ANOVA)]. Pre-treatment tumor volumes from MRI and bCT were correlated (r = 0.905, P < 0.001). Tumor size from post-treatment bCT was correlated with pathology (r = 0.987, P = 0.002) for invasive ductal carcinoma larger than 5 mm and the maximum difference in tumor size was 0.57 cm. The presence of biopsy clip (3 mm) limited the ability to accurately measure tumors smaller than 5 mm. All study participants were pathologically assessed to be responders, with three subjects experiencing complete pathologic response for invasive cancer and the reminder experiencing partial response. Compared to pre-treatment tumor volume, there was a statistically significant (P = 0.0003, paired t-test) reduction in tumor volume at mid-treatment observed with bCT, with an average tumor volume reduction of 47%. This pilot study suggests that dedicated non-contrast bCT has the potential to serve as an expedient imaging tool for monitoring tumor volume changes during NAC. Larger studies are needed in future.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mit dem steigenden Einsatz der neoadjuvanten Chemotherapie bei Patientinnen mit einem primär operablen Mammakarzinom erlangt die frühzeitige Evaluation des Therapieansprechens eine zunehmende Bedeutung.Die klinische Untersuchung, die Mammographie und die Hochfrequenzsonographie der Brust weisen für das Therapiemonitoring eine hohe Interobservervariabilität auf.Die Magnetresonanztomographie (MRT) bietet die Möglichkeit, neben der Tumorgröße und der Morphologie auch funktionelle Parameter zu erfassen und somit bereits früh im Therapieverlauf das Therapieansprechen vorherzusagen.Ziel einer frühen zuverlässigen Prädiktion des Therapieansprechens ist die Abstimmung der Therapie auf die individuelle Patientin.Der vorliegende Beitrag fasst die aktuellen Leitlinien zum Therapiemonitoring unter neoadjuvanter Chemotherapie des Mammakarzinoms gemäß den Response Evaluation Criteria In Solid Tumors (RECIST) zusammen, beschreibt die technischen Grundlagen des Therapiemonitorings mithilfe der funktionellen MRT und gibt einen Überblick über die aktuelle Studienlage zur klinischen Anwendbarkeit der funktionellen MRT im Rahmen des Therapiemonitorings.Die funktionelle MRT liefert im Rahmen von Studien vielversprechende Ansätze zur Evaluation des Therapieansprechens. Das Evidenzlevel ist für die dargestellten Verfahren der funktionellen MRT im Rahmen des Therapiemonitorings jedoch derzeit nicht ausreichend evaluiert.
    Der Radiologe 01/2014; 54(3). DOI:10.1007/s00117-013-2576-4 · 0.41 Impact Factor